信号淋巴细胞激活分子家族成员1结合可抑制系统性红斑狼疮中T细胞-B细胞相互作用并减少白细胞介素-6产生及浆母细胞分化
本研究在健康对照和系统性红斑狼疮(SLE)患者的外周血T细胞-B细胞共培养体系中,使用SLAMF1单克隆抗体进行干预。结果显示SLAMF1结合可减少T-B细胞结合体形成、B细胞白细胞介素-6(IL-6)产生、T细胞IL-21和IL-17A产生以及免疫球蛋白和自身抗体产生,并直接抑制分离B细胞的IL-6和Ig产生,但不影响分离T细胞的细胞因子产生。
要点
- SLAMF1单抗在健康对照和SLE患者中均减少T-B细胞结合体形成。
- SLAMF1单抗降低B细胞IL-6产生及T细胞IL-21和IL-17A产生。
- SLAMF1单抗直接抑制分离B细胞的IL-6和Ig产生,但不影响分离T细胞。
核心结论
- SLAMF1抗体抑制T细胞-B细胞相互作用并抑制B细胞细胞因子产生和分化,从而可能成为治疗SLE患者的潜在工具。
研究设计与样本
- 研究将健康供者或SLE患者经抗IgM预刺激的初始或总B细胞与自体T细胞在CD3/CD28刺激下共培养,并加入或不加入SLAMF1单克隆抗体。
- 初始B细胞在SLAMF1抗体存在下用抗IgM和CD40L刺激。
- 采用流式细胞术和/或定量聚合酶链反应检测CD4+ T细胞和B细胞的细胞因子产生。
- 采用流式细胞术评估浆母细胞形成和T细胞-B细胞结合体。
- 采用酶联免疫吸附试验测定IgG和抗核抗体产生。
主要发现
- 在健康对照和SLE患者中,SLAMF1结合均减少结合体形成、B细胞IL-6产生、T细胞IL-21和IL-17A产生以及Ig和自身抗体产生。
- SLAMF1单抗在体外直接作用于分离的外周B细胞,降低IL-6和Ig产生。
- SLAMF1单抗不影响体外刺激的分离T细胞的细胞因子产生。
临床怎么用
- 作者认为SLAMF1抗体通过抑制T细胞-B细胞相互作用并抑制B细胞细胞因子产生和分化,可能成为治疗SLE患者的潜在工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Signaling lymphocytic activation molecule family member 1 (SLAMF1) homophilic interactions promote immunoglobulin production and T cell-B cell cross-talk. SLAMF1 is overexpressed on T and B cells in patients with systemic lupus erythematosus (SLE). This study was undertaken to determine the role of SLAMF1 monoclonal antibody (mAb) in modulating T cell-B cell interaction and B cell activation. METHODS: Anti-IgM-prestimulated naive or total B cells from either healthy donors or patients with SLE were cocultured with autologous T cells under CD3/CD28 stimulation, in the presence or absence of the SLAMF1 mAb. Naive B cells were stimulated with anti-IgM and CD40L in the presence of the SLAMF1 antibody. Cytokine production by CD4+ T cells and B cells was examined by flow cytometry and/or quantitative polymerase chain reaction. Plasmablast formation and T cell and B cell conjugates were assessed by flow cytometry. IgG and antinuclear antibody production was determined by enzyme-linked immunosorbent assay. RESULTS: SLAMF1 ligation in a human peripheral blood T cell-B cell culture system reduced the following in both healthy controls and patients with SLE: conjugate formation, interleukin-6 (IL-6) production by B cells, IL-21 and IL-17A production by T cells, and Ig and autoantibody production. Whereas the SLAMF1 mAb directly affected the function of isolated peripheral B cells by decreasing IL-6 and Ig production in vitro, it did not affect cytokine production by isolated T cells stimulated in vitro. CONCLUSION: The SLAMF1 antibody inhibits T cell-B cell interaction and suppresses B cell cytokine production and differentiation, thereby acting as a potential therapeutic tool in the treatment of patients with SLE.
引用
- Karampetsou MP, Comte D, Suárez-Fueyo A, et al. Signaling Lymphocytic Activation Molecule Family Member 1 Engagement Inhibits T Cell-B Cell Interaction and Diminishes Interleukin-6 Production and Plasmablast Differentiation in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019. PMID: 30058241. doi:10.1002/art.40682
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。